1. Scrip
  2. >>Therapy Areas

Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market

Positive Top-Line Results From TULIP Study

 
• By John Davis

Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.

Guided Missiles
ADCs Are Often Likened To Guided Missiles • Source: Alamy

Netherlands-based Byondis B.V.’s lead candidate product, the next-generation antibody-drug conjugate, SYD985, has met its primary endpoint in the Phase III TULIP study in HER2-positive advanced breast cancer, and the company intends to explore partnering for the product, which it expects to submit for regulatory approval by the end of 2021. 

Although Byondis’s novel ADC would offer patients a new treatment option, it would be entering an increasingly crowded market for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.